
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

Supplementary Materials


SUPPLEMENTARY METHODS

Generation of GSDMB antibody


Two BALB/c mice were intra-peritoneal injected (three times at 14-day intervals) with 100 µg of a peptide comprising amino acids 208-406 of the C-terminal region of a His-GSDMB fusion protein and complete Freund's adjuvant (Difco). A 150 µg booster of the recombinant His-GSDMB protein was injected intra-peritoneally, and fused three days later by conventional methods. The cell fusion partner was the NS-1 myeloma cell line (P3/NS1/1-Ag4-1). Hybridoma supernatants were screened by ELISA and by western blot using HEK-293T cells transfected with pCDNA3-HA-Gasdemin B plasmid. The monoclonal antibody (mAb; clone GAS120C, isotype IgG2b) was cloned by limiting dilution. Antibody purification was performed with a Hi-Trap Protein G column (GE Healthcare, UK). Animal experiments were performed under the experimental protocol approved by the Institutional Committee for Care and Use of Animals (CEUCA 001/002). To confirm that the mAb recognized the human GSDMB protein, the HEK-293T cell line was transiently transfected with each of the GSDMB isoforms previously characterized [34]. Briefly, the HEK-293T cell line was transiently transfected with Lipofectamine 2000 (InvitroGen) and 4 µg of pEZ-M61 expression vectors (GeneCopoeia) containing the cDNA of each of the described GSDMB isoforms (isoform 1, NM 001042471.1; isoform 2, NM 018530.2; isoform 3 NM_001165958.1; and isoform 4, NM 001165959.1). After 48 h cells were lysed in RIPA buffer and 40 µg of total proteins were run in 15% SDS-PAGE Gels. Membranes were incubated overnight with the mouse monoclonal anti-GSDMB antibody described above (1:250 in 5% milk) and then with anti-mouse IgGs-HRP (1:5000; 1 h). Four bands matching the predicted size of each GSDMB isoform were detected. No additional (unspecific) bands were observed.



Supplementary Figure S1: *GSDMB* over-expression is associated with poor overall survival in HER2-positive breast cancers. Tumour samples with the top 25% mRNA expression levels of *GSDMB* gene ("high", red) show significantly worse prognosis than the remaining tumors ("low", green). Overall Survival curve in HER2-positive breast cancers patients from the Staaf dataset [38]. C Statistical differences, HR and *p*-value, were calculated via log-rank test.



Supplementary Figure S2: Anti-GSDMB antibody detects all GSDMB isoforms. Western blot analysis of GSDMB using our specific monoclonal antibody in HEK293 cells with over-expression of the characterized GSDMB isoforms [35] (G1, NM_001042471.1; G2, NM_018530.2; G3, NM_001165958.1; G4, NM_001165959.1). GAPDH was used as a loading control. Four bands matching the predicted size of each GSDMB isoform were detected. No additional (unspecific) bands were observed.



Supplementary Figure S3: Immunohistochemical expression of GSDMB in breast cancer Patient Derived Xenografts (PDX). (A) (PDX01): PDX derived from HER2-negative tumor; (B) (PDX288) and (C) (PDX118): HER2-positive cancers. PDX118 (c) was classified as sensitive and PDX288 (b) as resistant to *in vivo* trastuzumab treatment. (D) (PDX118T-R5): trastuzumab-resistant PDX originated from PDX118 (c) by chronic trastuzumab treatment *in vivo*. All the panels are shown at the same magnification x 20.

Dataset	Ur-Rehman 2013 (<i>n</i>	= 1570) ^a	TCGA 2012 $(n = 526)^{b}$	
Parameter	GSDMB High	GSDMB Low	GSDMB High	GSDMB Low
ER +	163/702 (23%)	539/702 (77%)	94/401 (23%)	307/401 (77%)
ER –	81/207 (39%)	126/207 (61%)	38/125 (30%)	87/125 (70%)
$X^2 p$ value	<i>p</i> = 0.001		P = 0.125	
PR +	52/231 (22.5%)	179/231 (77.5%)	69/340 (20%)	271/340 (80%)
PR –	12/53 (22.6%)	41/53 (77.4%)	63/186 (34%)	123/186 (66%)
$X^2 p$ value	<i>p</i> = 0.9		<i>p</i> = 0.001	
Grade I	17/153 (11%)	136/153 (89%)		
Grade II	84/445 (19%)	361/445 (81%)	N/A	N/A
Grade III	126/372 (34%)	246/372 (66%)		
$X^2 p$ value	p = 0.001			
LN +	28/143 (19.6%)	115/143 (80.4%)	77/258 (30%)	181/258 (70%)
LN –	242/946 (26%)	704/946 (74%)	55/268 (20%)	213/268 (80%)
$X^2 p$ value	<i>p</i> = 0.145		<i>p</i> = 0.016	
HER2+ IHC	33/63 (52.4%)	30/63 (47.6%)	50/75 (67%)	25/75 (33%)
HER2 – IHC	44/243 (18%)	199/243 (82%)	82/451 (18%)	369/451 (82%)
$X^2 p$ value	<i>p</i> < 0.001		<i>p</i> < 0.001	
Mol. Subtype (SAM) ^c	HER2 <i>p</i> < 0.001		HER2	
			<i>p</i> < 0.001	
ERBB2 Amp ^d			50/67 (75%)	17/67 (25%)
ERBB2 Norm	N/A	N/A	82/459 (18%)	377/459 (82%)
$X^2 p$ value			<i>p</i> < 0.001	
GSDMB Amp ^d			48/58 (83%)	10/58 (17%)
GSDMB Norm	N/A	N/A	84/468 (18%)	384/468 (82%)
$X^2 p$ value			<i>p</i> < 0.001	

Supplementary Table S1: High levels of GSDMB mRNA are associated with the HER2-positive phenotype in breast cancer microarray datasets

In silico analysis of GSDMB expression was performed in two independent gene expression datasets: ^a The Ur-Rehman dataset [36], a compilation of eight different studies performed on the HG-U133A Affymetrix platform, ^b TCGA (The Cancer Genome Atlas) study [37]. Normalized GSDMB expression was categorized as "high" when it was above the third quartile (top 25% expression) of all tumor samples; otherwise, it was considered "low". Association of GSDMB levels with clinical and pathological features was tested by Chi-square (X²). ^c Tumors were classified within the different molecular subtypes using the PAM50 classifier [38], and the association of GSDMB-high tumors with any of these types was tested by SAM [39] using ROCK statistical tools.^d Gene amplification (Amp) assessed by copy number aberration using Affymetrix 6.0 SNP arrays. Norm, normal (not amplified). In all statistical analyses a *p* value < 0.05 (considered significant) is highlighted in bold letters. ER, estrogen receptor; PR, progesterone Receptor; IHC, immunohistochemistry; N/A, data not available.

	Discovery series	Validation series	
	† <i>n</i> (%)	†n (%)	
Grade			
1	5/53 (9.4)	11/95 (11.6)	
2	25/53 (47.2)	26/95 (27.4)	
3	23/53 (43.4)	58/95 (61.1)	
Estrogen Receptor expression			
Negative	20/53 (37.7)	35/95 (36.8)	
Positive	33/53 (62.3)	60/95 (63.2)	
Progesterone Receptor expression			
Negative	29/52 (55.8)	49/93 (52.7)	
Positive	23/52 (44.2)	44/93 (47.3)	
HER2 amplification			
Negative	24/53 (45.3)	0	
Positive	29/53 (54.7)	95 (100)	
pCR*			
Responders	17/29 (58.6)	58/95 (61.1)	
Non-responders	12/29 (41.4)	37/95 (38.9)	
Relapse*			
No	21/26 (80.8)	47/66 (71.2)	
Yes	5/26 (19.2)	19/66 (28.8)	

Supplementary Table S2: Summary of clinical, pathological and immunohistochemical features of breast carcinomas included in discovery and validation series

The data make reference to the available cases for each marker. n (%), number of analyzed cases and (percentage). PCR: pathological complete response when there is no invasive presence of tumour at the breast or ganglia level and Relapse as local or distant recurrence in HER2-positive tumours.

Supplementary Table S3: GSDMB immunohistochemical expression and gene amplification (FISH) in HER2-positive breast carcinomas (n = 95) included in the validation series

	Validation series	
	* <i>n</i> (%)	
GSDMB amplification $(n = 95)$		
Negative	37 (38.9)	
Positive	58 (61.1)	
GSDMB expression $(n = 93)$		
Negative	29 (31.2)	
Positive	64 (68.8)	

**n* (%), number of analyzed cases and (percentage).

	† <i>n</i> (%)
Grade (<i>n</i> = 138)	
1	19 (13.8)
2	59 (42.8)
3	60 (43.4)
Estrogen receptor expression ($n = 104$)	
Negative	45 (43.3)
Positive	59 (56.7)
Progesterone receptor expression ($n = 127$)	
Negative	41 (32.3)
Positive	86 (67.7)
HER2 amplification $(n = 129)$	
Negative	76 (58.9)
Positive	53 (41.1)
GSDMB expression $(n = 133)$	
Negative	100 (75.2)
Positive	33 (24.8)
Lymph node metastasis $(n = 46)^*$	
Negative	22(44.9)
Positive	27 (55.1)
Distant metastasis ($n = 46$)*	
Negative	30 (65.2)
Positive	16 (34.8)

Supplementary Table S4: Summary of clinical, pathological and immunohistochemical features of breast carcinomas series treated with adjuvant regimens (n = 138)

*Only evaluated in HER2-positive breast carcinomas. $^{\dagger}n$ (%), number of analyzed cases and (percentage).